摘要
Immune checkpoint blockade(ICB)offers a new opportunity for treatment for gastric cancer(G.C.).Understanding the upstream regulation of immune checkpoints is crucial to further improve the efficacy of ICB therapy.Herein,using the CRISPR-Cas9-based genome-wide screening,we identified TRIM28 as one of the most significant regulators of PD-L1,a checkpoint protein,in G.C.cells.
基金
This work was supported by the joint fund for key projects of the National Natural Science Foundation of China(U20A20371)
the National Natural Science Foundation of China(Nos.81872502,82073312,81972758)
the third round of public welfare development and reform pilot projects of Beijing Municipal Medical Research Institutes(Beijing Medical Research Institute,2019-1)
Double First Class disciplinary development Foundation of Peking University(BMU2019LCKXJ011)
Capital’s funds for health improvement and research(2018-2-1023)
Beijing municipal administration of hospitals’youth program(No.QML20181102)
Beijing Municipal Administration of Hospitals Incubating Program(PX2019040)
Clinical Medicine Plus X-Young Scholars Project,Peking University(PKU2020LCXQ001,PKU2021LCXQ022)
the Science Foundation of Peking University Cancer Hospital(2020-6,2020-22,2020-23)
2021 Tai hu Talent Program Top Medical Expert Team(2021-THRC-DJ-PWK).
